The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials

Bill Gkogkas, Fatma Bektas, Hector Garcia Garcia, Yoshinobu Onuma, Takashi Muramatsu, V Farooq, Roberto Diletti, Robert Jan van Geuns, B de Bruyne, B Chevalier, L Thuesen, PC (Pieter) Smits, D Dudek, J Koolen, S Windecker, R Whitbourn, D McClean, C Dorange, K Miquel-Hebert, S VeldhofR Rapoza, JA Ormiston, PWJC (Patrick) Serruys

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)

Abstract

Aims: To assess serially the edge vascular response (EVR) of a bioresorbable vascular scaffold (BVS) compared to a metallic everolimus-eluting stent (EES). Methods and results: Non-serial evaluations of the Absorb BVS at one year have previously demonstrated proximal edge constrictive remodelling and distal edge changes in plaque composition with increase of the percent fibro-fatty (FF) tissue component. The 5 mm proximal and distal segments adjacent to the implanted devices were investigated serially with intravascular ultrasound (IVUS), post procedure, at six months and at two years, from the ABSORB Cohort B1 (n=45) and the SPIRIT II (n=113) tria Conclusions: The IVUS-based serial evaluation of the EVR up to two years following implantation of a bioresorbable everolimus-eluting scaffold shows a statistically significant proximal edge LL; however, this fmding did not seem to have any clinical implications in the serial assessment. The upcoming imaging follow-up of the Absorb BVS at three years is anticipated to provide further information regarding the vessel wall behaviour at the edges.
Original languageUndefined/Unknown
Pages (from-to)709-720
Number of pages12
JournalEuroIntervention
Volume9
Issue number6
DOIs
Publication statusPublished - 2013

Cite this